Palo Alto – March 31, 2015 – Cooley is advising Horizon Pharma plc on its agreement to acquire Hyperion Therapeutics for $1.1 billion in an all cash transaction and related debt commitments.
Horizon Pharma plc, which is headquartered in Dublin, Ireland, is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. Hyperion Therapeutics is a commercial-stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases.
Earlier this month, Cooley advised Horizon Pharma and Horizon Pharma Investments Limited on its Rule 144A offering of $400 million aggregate principal amount of exchangeable senior notes due 2022.
About Cooley LLP
Cooley's lawyers solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, often where innovation meets the law.
Cooley has 850 lawyers across 12 offices in the United States, China and Europe.